Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Phase Ib/II Study (NCT02488408 / BGBC003) of Bemcentinib Monotherapy or in Combination with Cytarabine or Decitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): FINAL Results

Blood (2023) 142 (Supplement 1): 4287.

https://doi.org/10.1182/blood-2023-181833

Published: 2023

Journal Articles

Targeting Venetoclax Resistance in TP53 -Mutated Acute Myeloid Leukemia

Ida Vänttinen, Tanja Ruokoranta, Joseph J Saad, Sari Kytölä, Monica Hellesøy, Stein-Erik Gullaksen, Pia-Sofia Ettala, Marja Pyörälä, Johanna Rimpiläinen, Timo Siitonen, Krister Wennerberg, Bjorn T. Gjertsen, Caroline A. Heckman, Mika Kontro, Heikki Kuusanmäki

Blood (2023) 142 (Supplement 1): 2927.

https://doi.org/10.1182/blood-2023-189340

Published: 2023

Journal Articles

Intradermal Vaccination with Vididencel in MRD+ AML-Patients Leads to Increase in Antigen Presenting Cells and T-Cells to the Injection Site, Visualized Using Imaging Mass Cytometry, Showing Local Immune Cell Interactions Leading to Systemic Immune Responses

Oystein Sefland, Reidun Kristin Kopperud, Hester Van Zeeburg, Jeroen Rovers, Maria Omsland, Arjan A. Van de Loosdrecht, Bjorn T. Gjertsen

Blood (2023) 142 (Supplement 1): 2942.

https://doi.org/10.1182/blood-2023-180813

Published: 2023

Journal Articles

AML Treatment By the AXL Inhibitor Bemcentinib in Combination with Cytarabine Shows Clinical Efficacy Related to TNFα and Cytotoxic Immune Cells: A Single-Cell Translational Study from the BGBC003 Trial

Blood (2023) 142 (Supplement 1): 1540.

https://doi.org/10.1182/blood-2023-185499

Published: 2023

Journal Articles

Vaccination Using an Allogeneic Leukemia-Derived Dendritic Cell Vaccine, Maintains and Improves Frequencies of Circulating Antigen Presenting Dendritic Cells Correlating with Relapse Free and Overall Survival in AML Patients

Hester Van Zeeburg, Eva Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina Van Elssen, Aristoteles Giagounidis, Soren Lehmann, Jeroen Rovers, Bjorn T. Gjertsen, Arjan A. van de Loosdrecht

Blood (2023) 142 (Supplement 1): 2957.

https://doi.org/10.1182/blood-2023-188573

Published: 2023

Journal Articles

Induction of Cellular and Humoral Immune Responses Is Associated with Durable Remissions in MRD+ AML-Patients after Maintenance Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Arjan A. van de Loosdrecht, Eva Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina Van Elssen, Aristoteles Giagounidis, Soren Lehmann, Hester Van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2023) 142 (Supplement 1): 769.

https://doi.org/10.1182/blood-2023-185532

Published: 2023

Journal Articles

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

Blood (2023) 142 (Supplement 1): 323.

https://doi.org/10.1182/blood-2023-184703

Published: 2023

Journal Articles

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1572.

https://doi.org/10.1182/blood-2023-181709

Published: 2023

Journal Articles

Prospective validation of the prognostic relevance of CD34 + CD38 – AML stem cell frequency in the HOVON-SAKK132 trial

Blood (2023) 141 (21): 2657–2661.

https://doi.org/10.1182/blood.2022019160

Published: 2023

Includes: Supplemental data

Journal Articles

Overlapping features of therapy-related and de novo NPM1 -mutated AML

Blood (2023) 141 (15): 1846–1857.

https://doi.org/10.1182/blood.2022018108

Published: 2023

Includes: Supplemental data

Journal Articles

Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion

Arjan A. Van de Loosdrecht, Jacqueline Cloos, Eva-Maria Wagner-Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina van Elssen, Aristoteles Giagounidis, Marij J.P. Welters, Sjoerd H. van der Burg, Hester J.T. van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2022) 140 (Supplement 1): 3410–3411.

https://doi.org/10.1182/blood-2022-163116

Published: 2022

Journal Articles

Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Arjan A. Van de Loosdrecht, Jacqueline Cloos, Eva-Maria Wagner-Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina van Elssen, Aristoteles Giagounidis, Sören Lehmann, Hester J.T. van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2022) 140 (Supplement 1): 1714–1715.

https://doi.org/10.1182/blood-2022-162169

Published: 2022

Journal Articles

Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses

Blood (2021) 138 (Supplement 1): 3410.

https://doi.org/10.1182/blood-2021-147225

Published: 2021

Journal Articles

Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in AML Patients Shows MRD Conversion and Improved Survival

Arjan A. Van de Loosdrecht, Jacqueline Cloos, Eva Maria Wagner, Uwe Platzbecker, Tobias A. W. Holderried, Janine van Elssen, Aristoteles Giagounidis, Soren Lehmann, Hester van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2021) 138 (Supplement 1): 1274.

https://doi.org/10.1182/blood-2021-148333

Published: 2021

Journal Articles

The Transmembrane Protein CD37 Is Not a Promising Therapeutic Target in Acute Myeloid Leukaemia

Tara Helen Dowling Dowling Steinsland, MSc, Stein-Erik Gullaksen, MS, PhD, Geir Bredholt, PhD, Calum Leitch, PhD, Mireia Mayoral Safont, BS, Øystein Bruserud, MD PhD, Mihaela Popa, Astri Maaland, Helen Heyerdahl, PhD, Jostein Dahle, PhD, Bjorn T. Gjertsen, MD PhD, Emmet Mccormack, BSc, PhD

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-142899

Published: 2020

Journal Articles

The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-136566

Published: 2020

Journal Articles

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Bjørn T. Gjertsen, MD PhD, Andreas Hochhaus, MD, Gianantonio Rosti, MD, Justin M. Watts, MD, Guillermo Ortí, Philipp le Coutre, MD, Eric Leip, PhD, Andrea Viqueira, MD, Jorge E. Cortes, MD, Frank Giles, MD, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 1639.

https://doi.org/10.1182/blood-2019-121815

Published: 2019

Journal Articles

Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Carlo Gambacorti-Passerini, MD, Tim H Brümmendorf, MD, Bjorn T. Gjertsen, MD PhD, Camille Abboud, MD, Gianantonio Rosti, MD, Elisabetta Abruzzese, MD, Eric Leip, PhD, Andrea Viqueira, MD, Valentín García Gutiérrez, PhD, Frank Giles, MD, Andreas Hochhaus, MD

Blood (2019) 134 (Supplement_1): 2936.

https://doi.org/10.1182/blood-2019-121813

Published: 2019

Journal Articles

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Blood (2019) 134 (Supplement_1): 3943.

https://doi.org/10.1182/blood-2019-128683

Published: 2019

Journal Articles

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Robert J. Kreitman, MD, Claire E. Dearden, MD FRCP, FRCPath, Pier Luigi Luigi Zinzani, MD, Julio Delgado, Tadeusz Robak, MD, Philipp D le Coutre, MD, Bjorn T. Gjertsen, MD PhD, Xavier Troussard, MD, Gail J. Roboz, MD, Lionel Karlin, MD, Douglas E Gladstone, MD, Nataliya Kuptsova-Clarkson, MD, Shiyao Liu, Priti Patel, MD, Wyndham Wilson, MD, Ira Pastan, MD, Francis J. Giles, MD FRCPI, FRCPath

Blood (2019) 134 (Supplement_1): 2808.

https://doi.org/10.1182/blood-2019-122307

Published: 2019

NARROW

Phase Ib/II Study (NCT02488408 / BGBC003) of Bemcentinib Monotherapy or in Combination with Cytarabine or Decitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): FINAL Results

Targeting Venetoclax Resistance in TP53 -Mutated Acute Myeloid Leukemia

Intradermal Vaccination with Vididencel in MRD+ AML-Patients Leads to Increase in Antigen Presenting Cells and T-Cells to the Injection Site, Visualized Using Imaging Mass Cytometry, Showing Local Immune Cell Interactions Leading to Systemic Immune Responses

AML Treatment By the AXL Inhibitor Bemcentinib in Combination with Cytarabine Shows Clinical Efficacy Related to TNFα and Cytotoxic Immune Cells: A Single-Cell Translational Study from the BGBC003 Trial

Vaccination Using an Allogeneic Leukemia-Derived Dendritic Cell Vaccine, Maintains and Improves Frequencies of Circulating Antigen Presenting Dendritic Cells Correlating with Relapse Free and Overall Survival in AML Patients

Induction of Cellular and Humoral Immune Responses Is Associated with Durable Remissions in MRD+ AML-Patients after Maintenance Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies

The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia

Prospective validation of the prognostic relevance of CD34 + CD38 – AML stem cell frequency in the HOVON-SAKK132 trial

Overlapping features of therapy-related and de novo NPM1 -mutated AML

Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion

Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses

Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in AML Patients Shows MRD Conversion and Improved Survival

The Transmembrane Protein CD37 Is Not a Promising Therapeutic Target in Acute Myeloid Leukaemia

The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Moxetumomab Pasudotox-Tdfk in Heavily Pretreated Patients with Relapsed/Refractory Hairy Cell Leukemia (HCL): Long-Term Follow-up from the Pivotal Phase 3 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only